Structure-guided minimalist redesign of the L-fuculose-1-phosphate aldolase active site: Expedient synthesis of novel polyhydroxylated pyrrolizidines and their inhibitory properties against glycosidases and intestinal disaccharidases

Chemistry - A European Journal

Volumn 16, Issue 35, 2010, Pages 10691-10706

  Garrabou, Xavier ^a   Gómez, Livia ^a   Joglar, Jesús ^a   Gil, Sergi ^b   Parella, Teodor ^b   Bujons, Jordi ^a   Clapés, Pere ^a  

^a CSIC   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Aldol reaction; Enzyme catalysis; Inhibitors; Mutagenesis; Pyrrolizidines

Indexed keywords

ACTIVE SITE; ALDOL ADDITION; ALDOL REACTIONS; AMINO ALDEHYDES; CATION INTERACTIONS; DIASTEREOISOMERS; DIHYDROXYACETONE PHOSPHATE; E. COLI; ENZYME CATALYSIS; FUCULOSE-1-PHOSPHATE ALDOLASE; GLYCOSIDASES; HYDROPHOBIC POCKETS; INHIBITORS; MOLECULAR MODELS; PYRROLIZIDINES; RIGID SUBSTRATES; STEREO-SELECTIVE; STERICALLY DEMANDING; SYN-ALDOLS; VARIABLE RATIO; WILD TYPES;

ALDEHYDES; CATALYSIS; CONDENSATION REACTIONS; ENZYMES; ESCHERICHIA COLI; HYDROXYLATION; MUTAGENESIS; STEREOCHEMISTRY; SYNTHESIS (CHEMICAL);

SUBSTRATES;

1,4 DIDEOXY 1,4 IMINOARABINITOL; 1,4-DIDEOXY-1,4-IMINOARABINITOL; ALDEHYDE; ARABINOSE; DISACCHARIDASE; ENZYME INHIBITOR; GLYCOSIDASE; IMINOSUGAR; L FUCULOSEPHOSPHATE ALDOLASE; L-FUCULOSEPHOSPHATE ALDOLASE; LYASE; SUGAR ALCOHOL;

ANIMAL; ARTICLE; CATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; ENZYME ACTIVE SITE; ESCHERICHIA COLI; HYDROXYLATION; MALE; METABOLISM; RAT; SITE DIRECTED MUTAGENESIS; SPRAGUE DAWLEY RAT; STEREOISOMERISM;

ALDEHYDE-LYASES; ALDEHYDES; ANIMALS; ARABINOSE; CATALYSIS; CATALYTIC DOMAIN; DISACCHARIDASES; ENZYME INHIBITORS; ESCHERICHIA COLI; GLYCOSIDE HYDROLASES; HYDROXYLATION; IMINO FURANOSES; MALE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; SUGAR ALCOHOLS;

EID: 77956656165     PISSN: 09476539     EISSN: 15213765     Source Type: Journal    
DOI: 10.1002/chem.201000714     Document Type: Article

References (74)

1. a) R. Mahrwald, Modem Aldol Reactions, Vol. 1: Enolates, Organocatalysis, Biocatalysis and Natural Product Synthesis, Wiley-VCH, Weinheim, 2004, p. 335;
2. b) R. Mahrwald, Modern Aldol Reactions, Vol. 2: Metal Catalysis, Wiley-VCH, Weinheim, 2004, p. 335;
3. c) S. M. Dean, W. A. Greenberg, C.-H. Wong, Adv. Synth. Catal. 2007, 349, 1308-1320;
4. d) W.-D. Fessner in Biocatalytic C-C Bond Formation in Asymmetric Synthesis (Eds.: D. Enders, K.-E. Jaeger), WileyVCH, Weinheim, 2007, pp. 351-375.
5. W. D. Fessner, G. Sinerius, Angew. Chem. 1994, 106, 217-220;
6. Angew. Chem. Int. Ed. Engl. 1994, 33, 209-212.
7. W.-D. Fessner, C. Walter, Top. Curr. Chem. 1997, 186-193, 97-194.
8. L. Espelt, J. Bujons, T. Parella, J. Calveras, J. Joglar, A. Delgado, P. Clapes, Chem. Eur. J. 2005, 11, 1392-1401.
9. L. Espelt, T. Parella, J. Bujons, C. Solans, J. Joglar, A. Delgado, P. Clapés, Chem. Eur. J. 2003, 9, 4887-4899.
10. J. Calveras, M. Egido-Gabás, L. Gómez, J. Casas, T. Parella, J. Joglar, J. Bujons, P. Clapés, Chem. Eur. J. 2009, 15, 7310-7328.
11. J. Calveras, J. Casas, T. Parella, J. Joglar, P. Clapés, Adv. Synth. Catal. 2007, 349, 1661-1666.
12. A. Bolt, A. Berry, A. Nelson, Arch. Biochem. Biophys. 2008, 474, 318-330.
13. A. C. Joerger, C. Gosse, W.-D. Fessner, G. E. Schulz, Biochemistry 2000, 39, 6033-6041.
14. At 4°C the rate of DHAP degradation was minimised and sometimes the conversions to aldol adducts were highly enhanced; see reference [12].
15. In all experiments conducted thus far the amount of biocatalyst employed in synthetic experiments with N-Cbz-amino aldehydes was adjusted to the amount (i.e., mg) of FucA wild type used rather than to the activities on FuclP, due to the disparate values of activity observed with this substrate.
16. T. Suau, G. Alvaro, M. D. Benaiges, J. Lopez-Santín, Biotechnol. Bioeng. 2006, 93, 48-55.
17. We were not able to separate the anti/syn diastereomers of the aldol adduct (5S)-4a on the preparative HPLC. Therefore this compound was assayed as a diastereomeric mixture 1:1 anti/syn.
18. M. K. Dreyer, G. E. Schulz, Acta Crystallogr. Sect. D 1996, 52, 1082-1091.
19. A. C. Joerger, C. Mueller-Dieckmann, G. E. Schulz, J. Mol. Biol. 2000, 303, 531-543.
20. a) J. R. Liddell, Nat. Prod. Rep. 2001, 18, 441-447;
21. b) L. Rambaud, P. Compain, O. R. Martin, Tetrahedron: Asymmetry 2001, 12, 1807-1809;
22. c) I. Izquierdo, M. T. Plaza, F. Franco, Tetrahedron: Asymmetry 2002, 13, 1581-1585;
23. d) I. Izquierdo, M. T. Plaza, F. Franco, Tetrahedron: Asymmetry 2003, 14, 3933-3935;
24. e) I. Izquierdo, M. T. Plaza, R. Robles, C. Rodriguez, A. Ramirez, A. J. Mota, Eur. J. Org. Chem. 1999, 1269-2174;
25. f) I. Izquierdo, M. T. Plaza, J. A. Tamayo, Tetrahedron: Asymmetry 2004, 15, 3635-3642;
26. g) I. Izquierdo, M. T. Plaza, J. A. Tamayo, D. L. Re, F. Sánchez-Cantalejo, Synthesis 2008, 1373-1378;
27. h) I. Izquierdo, M. T. Plaza, V. Yanez, Tetrahedron 2007, 63, 1440-1447;
28. i) F. Cardona, E. Faggi, F. Liguori, M. Cacciarini, A. Goti, Tetrahedron Lett. 2003, 44, 2315-2318;
29. j) T. J. Donohoe, M. D. Cheeseman, T. J. G O'Riordan, J. A. Kershaw, Org. Biomol. Chem. 2008, 6, 3896-3898;
30. k) L. Chabaud, Y. Landais, P. Renaud, Org. Lett. 2005, 7, 2587-2590;
31. i) J. A. Tamayo, F. Franco, D. Lo Re, F. Sanchez-Cantalejo, J. Org. Chem. 2009, 74, 5679-5682.
32. I. Izquierdo, M. T. Plaza, F. Franco, Tetrahedron: Asymmetry 2004, 15, 1465-1469.
33. I. Izquierdo, M. T. Plaza, R. Robles, F. Franco, Tetrahedron: Asymmetry 2001, 12, 2481-2487.
34. I. Izquierdo, M. T. Plaza, J. A. Tamayo, F. Sanchez-Cantalejo, Tetrahedron: Asymmetry 2007, 18, 2211-2217.
35. I. Izquierdo, M. T. Plaza, J. A. Tamayo, V. Yanez, D. Lo Re, F. Sanchez-Cantalejo, Tetrahedron 2008, 64, 4613-4618.
36. D. Koch, S. Maechling, S. Blechert, Tetrahedron 2007, 63, 7112-7119.
37. J.-B. Behr, A. Erard, G. Guillerm, Eur. J. Org. Chem. 2002, 1256-1262.
38. D. Chikkanna, O. V. Singh, S. B. Kong, H. Han, Tetrahedron Lett. 2005, 46, 8865-8868.
39. a) R. J. Nash, L. E. Fellows, J. V. Dring, G. W. J. Fleet, A. E. Derome, T. A. Hamor, A. M. Scofield, D. J. Watkin, Tetrahedron Lett. 1988, 29, 2487-2490;
40. b) A. Kato, I. Adachi, M. Miyauchi, K. Ikeda, T. Komae, H. Kizu, Y. Kameda, A. A. Watson, R. J. Nash, M. R. Wormald, Carbohydr. Res. 1999, 316, 95-103.
41. R. J. Nash, L. E. Fellows, J. V. Dring, G. W. J. Fleet, A. Girdhar, N. G. Ramsden, J. M. Peach, M. P. Hegarty, A. M. Scofield, Phytochemistry 1990, 29, 111-114.
42. N. Asano, H. Kuroi, K. Ikeda, H. Kizu, Y. Kameda, A. Kato, I. Adachi, A.A. Watson, R. J. Nash, G. W. J. Fleet, Tetrahedron: Asymmetry 2000, 11, 1 -8.
43. T. Yamashita, K. Yasuda, H. Kizu, Y. Kameda, A. A. Watson, R. J. Nash, G. W. J. Fleet, N. Asano, J. Nat. Prod. 2002, 65, 1875-1881.
44. a) From Synthesis Iminosugars to Therapeutic Applications (Eds. : P. Compain, O. R. Martin), Wiley, New York, 2007, p. 467;
45. c) J. Churruca, L. Vigil, E. Luna, J. Ruiz-Galiana, M. Varela, Diabete Metab. 2008, 1, 3-11;
46. d) A. Esteghamati, O. Khalilzadeh, M. Anvari, M. S. Ahadi, M. Abbasi, A. Rashidi, Arch. Med. Res. 2008, 39, 803-808;
47. e) K. Kim, S. H. Yun, B. Y. Choi, M. K. Kim, Br. J. Nutr. 2008, 100, 576-584;
48. f) L. R. Reynolds, Nutraceuticals, Glycemic Health Type 2 Diabetes, Wiley-Blackwell, New York, 2008, pp. 65-86.
49. O. Affolter, A. Baro, W. Frey, S. Laschat, Tetrahedron 2009, 65, 6626-6634.
50. a) A. Kato, E. Kano, I. Adachi, R. J. Molyneux, A. A. Watson, R. J. Nash, G. W. J. Fleet, M. R. Wormald, H. Kizu, K. Ikeda, N. Asano, Tetrahedron: Asymmetry 2003, 14, 325-331;
51. b) T. J. Donohoe, R. E. Thomas, M. D. Cheeseman, C. L. Rigby, G. Bhalay, I. D. Linney, Org. Lett. 2008, 10, 3615-3618.
52. S. Desvergnes, S. Py, Y. Vallee, J. Org. Chem. 2005, 70, 1459-1462.
53. N. Asano, K. Ikeda, L. Yu, A. Kato, K. Takebayashi, I. Adachi, I. Kato, H. Ouchi, H. Takahata, G.W.J. Fleet, Tetrahedron: Asymmetry 2005, 16, 223-229.
54. A. E. Stutz, Iminosugars as Glycosidase Inhibitors: Nojirimycin and Beyond, Wiley-VCH, Weinheim, 1999, p. 397.
55. A. L. Concia, C. Lozano, J. A. Castillo, T. Parella, J. Joglar, P. Clapés, Chem. Eur. J. 2009, 15, 3808-3816.
56. J. A. Castillo, J. Calveras, J. Casas, M. Mitjans, M. P. Vinardell, T. Parella, T. Inoue, G. A. Sprenger, J. Joglar, P. Clapés, Org. Lett 2006, 8, 6067-6070.
57. Evaluation of Enzyme Inhibitors in Drug Discovery: A. Guide to Medicinal Chemists and Pharmacologists (Ed.: R. A. Copeland), WileyInterscience, New York, 2005, p. 296.
58. S.-H. Jung, J.-H. Jeong, P. Miller, G-H. Wong, J. Org. Chem. 1994, 59, 7182-7184.
59. W. D. Fessner, A. Schneider, O. Eyrisch, G. Sinerius, J. Badia, Tetrahedron: Asymmetry 1993, 4, 1183-1192.
60. L. Vida, PhD Thesis, Universitat Autonoma de Barcelona (Spain), 2006.
61. Z. Q. Zhang, A. G. Marshall, J. Am. Soc. Mass Spectrom. 1998, 9, 225-233.
62. L. Vidal, O. Durany, T. Suau, P. Ferrer, M. D. Benaiges, G. Caminal, J. Chem. Technol. Biotechnol. 2003, 78, 1171-1179.
63. O. Durany, G. Caminal, C. de Mas, J. Lopez-Santin, Process Biochem. 2004, 39, 1677-1684.
64. L. Espelt, P. Clapés, J. Esquena, A. Manich, C. Solans, Langmuir 2003, 19, 1337-1346.
65. J. R. Luly, J. F. Dellaria, J. J. Plattner, J. L. Soderquist, N. Yi, J. Org. Chem. 1987, 52, 1487-1492.
66. A. Dahlqvist, Anal. Biochem. 1964, 7, 18-25.
67. M. M. Bradford, Anal. Biochem. 1976, 72, 248-254.
68. J. Calveras, J. Bujons, T. Parella, R. Crehuet, L. Espelt, J. Joglar, P. Clapés, Tetrahedron 2006, 62, 2648-2656.
69. a) T. A. Halgren, J. Comput. Chem. 1999, 20, 730-748;
70. b)T. A. Halgren, J. Comput. Chem. 1999, 20, 720-729.
71. P. Labute, J. Comput. Chem. 2008, 29, 1693-1698.
72. W. L. Jorgensen, D. S. Maxwell, J. TiradoRives, J. Am. Chem. Soc. 1996, 118, 11225-11236.
73. W. C. Still, A. Tempczyk, R. C. Hawley, T. Hendrickson, J. Am. Chem. Soc. 1990, 112, 6127-6129.
74. H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, P. E. Bourne, Nucleic Acids Res. 2000, 28, 235-242.